Monitoring disease activity in myocarditis is important for tailored therapeutic strategies. This study evaluated the ability of T1 and T2 mapping cardiovascular magnetic resonance (CMR) to monitor the course of myocardial inflammation in healing myocarditis. 
Introduction
The course of myocarditis is subject to substantial individual variations with important clinical implications. 1, 2 Healed myocarditis can be indirectly assumed in the absence of persisting symptoms if myocardial function and biomarkers have normalized, 3 but direct assessment of myocardial inflammation ultimately requires endomyocardial biopsy (EMB). 1,2 Persistent myocardial inflammation, on the other hand, is currently perceived as the key factor for progression of myocarditis into dilative cardiomyopathy (DCM) and constitutes a potential target for specific therapeutic regimes. 1, 4 myocarditis for tailored therapeutic interventions. 1 Standard 'LakeLouise' cardiovascular magnetic resonance (CMR) criteria 5 have been used in this context, 6 but turned out to be of limited value to detect myocardial inflammation in certain sub-types of myocarditis 7 and in patients with more chronic clinical presentation. 8, 9 Therefore, EMB is currently recommended for assessing disease activity by detecting ongoing myocardial inflammation 1 . T1 and T2 mapping are emerging CMR tools for quantitative tissue characterization, which may overcome some limitations of the 'LakeLouise' criteria. [9] [10] [11] [12] [13] [14] In particular, native myocardial T1 seems to provide incremental information on the stage of the disease 15, 16 and myocardial T2 appears to be able to assess ongoing myocardial inflammation as defined by EMB. 9, 14 Nevertheless, there is a paucity of longitudinal data on T1 and T2 mapping parameters to assess the activity of myocarditis. We therefore prospectively evaluated T1 and T2 mapping CMR in the acute phase, at 3-months and at 12-months FU in population with strictly defined acute myocarditis. The major objectives were to assess, whether T1 and T2 mapping CMR have the ability (i) to describe the course of myocardial inflammation after acute myocarditis, (ii) to discriminate diseased patients from healthy individuals in different stages of myocarditis, and (iii) to differentiate acute from healed stages of myocarditis.
Methods

Study population and design
The local ethics committee approved the study and all subjects gave their written informed consent. We prospectively included 73 consecutive patients with suspected myocarditis, who underwent clinically indicated CMR. Concomitant coronary artery disease (CAD) was excluded as clinically indicated. A comprehensive cardiac evaluation was performed at baseline (BL), 3-months FU, and 12-months FU by standardized questionnaires, blood-samples, echocardiography, and CMR.
We applied a strict definition for acute myocarditis in order to confine the final study population to patients with unambiguously acute myocarditis at BL (Figure 1 ). This definition takes into account the specific diagnostic needs in the different subgroups of myocarditis:
7 First, 27 patients with 'infarct-like' presentation were clinically accepted as acute myocarditis who presented within 14 days after onset of chest pain with dynamically elevated troponin T values in combination with positive 'Lake-Louise' CMR criteria, 5 including typical non-ischemic, (sub)epicardial, or midwall late-gadolinium-enhancement (LGE) patterns. Secondly, 21 patients with 'cardiomyopathy-like' presentation, who had recent-onset heart failure and reduced left-ventricular (LV) function, were only accepted if active myocardial inflammation was approved by clinically indicated EMB ( Figure 1) . Thus, we consequently excluded ambiguous cases, taking account of recent findings on the limited diagnostic performance of CMR in 'cardiomyopathy-like' myocarditis compared with 'infarct-like' myocarditis. 7, 8, 14, 16 This specific definition represents a clinically applicable compromise between the need for a clear diagnosis of acute myocarditis on the one hand and the avoidance of EMB on the other hand. Thus, the final study population consisted of 48 patients with strictly defined acute myocarditis ( Figure 1 ). Patients were excluded from FU if a CMR FU was denied or contraindicated ( Figure 1 ). In addition, 27 healthy individuals with a similar age and gender distribution served as controls for CMR tissue characterization, including subjects of a recently published control group. 12, 14 CMR protocol and data analyses CMR was performed at 1.5-T (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol has been established and published in detail before. 12, 14 Briefly, the CMR protocol consisted of a conventional cine, edema-sensitive, early myocardial enhancement, and LGE CMR as well as T1 and T2 mapping on three representative short-axis positions. T1 mapping was performed by using a modified look locker inversion recovery (MOLLI) sequence with a '3(3)5' scheme before and 15 min after contrast-media administration. 12,17,18 T2 mapping was performed using a Figure 1 Flow chart study population. Acute myocarditis was defined clinically in patients with 'infarct-like' presentation and by EMB in patients with 'cardiomyopathy-like' presentation. The initial study population included 73 patients with clinically suspected myocarditis. We excluded 25 patients because of the absence of active myocardial inflammation on EMB (n = 12) or declined/not-indicated EMB in 'cardiomyopathy-like' patients (n = 11), amyloidosis (n = 1) on EMB, and concomitant CAD (n = 1). Thus, the final study population consisted of 48 patients with strictly defined acute myocarditis. Nine patients were lost to 3-months and 18 patients to 12-months FU, respectively. Figure 2 demonstrates global and regional measurements of native myocardial T1, T2, and ECV. Regional T1, T2, and ECV was measured in LGE positive myocardium of the 36 LGE positive patients by manually drawing a region-of-interest (ROI) on the LGE image around the lesions and copying theses ROIs to the corresponding T1, T2, and ECV maps, respectively. The Supplementary data online provides data that are more detailed.
Statistical analysis
Statistical analyses were performed using R for Windows, version 3.3.0 (RStudio, Boston MA, USA), MedCalc for Windows, version 13.3.3.0 (MedCalc Software, Ostend, Belgium) and GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA). Continuous data are presented as median with first and third quartiles (Q1-Q3). Categorical data are presented as numbers and percentage. First, a linear mixed model ANOVA was used to test for any difference (i) between the control group and diseased patients in the acute phase, at 3-months and at 12-months FU and (ii) between the three diseased patient groups. These global tests were followed by Bonferroni-corrected pairwise comparisons of (i) controls with the three diseased patient groups and (ii) the acute phase group with the two FU groups. Secondly, the performances of CMR parameters to discriminate (i) diseased patients from healthy controls at different stages of the disease and (ii) acute (n = 48) from chronic stages of myocarditis (n = 21) were assessed by receiveroperating characteristic (ROC) analyses. The Youden index was used to depict optimal cut-off values from the ROC curves. Sensitivities, specificities, and accuracies were calculated for these cut-off values with 95% confidence intervals. The De Long method was used to compare different areas under the curves (AUCs). Two-sided P-values were calculated and statistical significance was defined as P < 0.05.
Results
Clinical characteristics
None of the patients had recurrent chest pain or dyspnea >NYHA-class 2 at FU. Median Troponin T values were significantly elevated in the acute phase, and normalized at 3-months and 12-months FU ( Table 1) . Median LVEF significantly improved from BL to 3-months and 12-months FU ( Table 1) . Diastolic LV function, as defined by the E/E' ratio on echocardiography, also significantly improved from BL to 3-months and 12-months FU ( Table 1 ). In particular, systolic and diastolic LV function recovered in patients with 'cardiomyopathy-like' myocarditis, whereas patients with 'infarct-like' myocarditis had initially normal LV function, which remained stable at 3-months and 12-months FU (see Supplementary data online, Tables S1.1 and S1.2). Figure 3 shows a typical example for the course of LGE native myocardial T1, and T2 in a patient with myocarditis. We found that median global native myocardial T1, T2, and ECV were significantly elevated compared with controls in the acute phase, but not at 3-months and 12-months FU ( Table 1 and Figure 4) . Furthermore, global and regional native myocardial T1, T2, and ECV were significantly higher in the acute phase compared with 3-months and 12-months FUs, respectively (Figure 4 ). The course of native myocardial T1 and T2 was similar in 'cardiomyopathy-like' and 'infarct-like' myocarditis, but global and regional ECV remained elevated in the subgroup of 'cardiomyopathy-like' myocarditis (see Supplementary data online, Tables S1.1 and S1.2). There was a weak correlation between the change in LVEF and the change in LGE mass (r = 0.37; P = 0.04), but not with the change in native T1, T2, and ECV, respectively.
CMR characteristics
Identification of diseased patients at different stages of myocarditis
The recently proposed 'LGE/ECV' approach uses presence of nonischemic LGE or an ECV > _ 27% in patients without LGE to identify diseased patients. 12 This approach had the best diagnostic accuracies of all methods at all disease stages with 91% (95% CI, 82-96%) in the acute stage, 86% (95% CI, 76-93%) at 3-months FU, and 85% (95% CI, 72-93%) at 12-months FU ( Figure 5 ). The Supplementary data online provides data that are more detailed.
Acute vs. healed myocarditis
Global native T1 and T2 provided good performances to discriminate acute from healed stages (12-months FU) with AUCs of 0.85 (95% CI, 0.76-0.94) and 0.83 (95% CI, 0.73-0.93) ( Figure 6 ). Optimal cutoff values of global native T1 and T2 to identify acute myocarditis were >1099 and >60 ms with sensitivities/specificities/accuracies of 59/95/70 and 64/95/74%, respectively. The performance of the global T2w-ratio to discriminate acute from healed stages was fair with an AUC of 0.73 (95% CI, 0.60-0.86), but not significantly inferior compared with T1 and T2 mapping. Regional native T1 and T2 in LGE positive myocardium provided excellent AUCs with 0.97 (95% CI, 0.93-1.02) and 0.93 (95% CI, 0.85-1.01) ( Figure 6 ). Optimal cut-off values of regional native T1 and T2 in LGE positive myocardium to identify acute myocarditis were >1108 and >59 ms with sensitivities/ specificities/accuracies of 97/92/97 and 87/91/88%, respectively. The AUC of the regional T2w-ratio in LGE was 0.83 (95% CI, 0.72-0.95) and significantly inferior compared with regional nT1 in LGE. Table  S1 .2 of the Supplementary data online provides data that are more detailed.
Discussion
This study prospectively evaluated T1 and T2 mapping CMR up to a 12-months FU period in a population with strictly defined acute myocarditis. The major findings were that (i) native myocardial T1 and T2 normalized with healing of myocarditis, (ii) a combination of LGE and ECV had the best diagnostic accuracy to identify diseased patients independent from disease stage, and (iii) native myocardial T1 and T2 provided an excellent performance to differentiate acute from healed stages. Figure 2 Example CMR measurements. (A) demonstrates measurements of global native myocardial T1 in a patient with myocarditis using the OsiriX TM software. Endo-and epicardial contours were manually drawn, meticulously avoiding potential contamination by blood pool and/or epicardial fat. Global myocardial T1 was then calculated as the mean of three short-axis slices. A separate blood-pool contour was drawn for calculating ECV maps. (B) demonstrates native T1 measurements in myocardium with LGE in the same patient. A ROI was drawn on the LGE image (B.1) and copied to the corresponding T1 map (B.2). Global and regional measurements of native T1, post-contrast T1, ECV, and T2 were performed in a similar fashion.
T1 and T2 mapping CMR imaging to monitor myocardial inflammation in healing myocarditis
Standard 'Lake-Louise' parameters
LGE is a central CMR criterion in myocarditis, 5 but persists in the vast majority of patients without ongoing myocardial inflammation. 6, 14 We found a decrease in LGE mass, associated with recovery of LV function, but persistent LGE lesions in our study population ( Table 1) . On the one hand, this observation highlights the excellent value of LGE to differentiate diseased patients from healthy individuals, independent from the disease stage. On the other hand, this finding shows that a positive LGE finding in a patient with suspected myocarditis may require additional information on disease activity. Zagrosek et al. 6 reported that the T2w-ratio and early global relative enhancement (gRE) enabled monitoring of myocardial injury by CMR in a population with clinically defined myocarditis. We found a decline of the T2w-ratio, but not gRE with healing of myocarditis ( Table 1) . Moreover, the performance of both parameters to discriminate acute from healed disease stages did not reach native myocardial T1 and T2 ( Figure 6 ). These findings are in line with recent data on the poor association of EMB defined myocardial inflammation with the T2w-ratio and gRE.
9,14
Native myocardial T1
Hinojar et al. 15 recently proposed a native T1-based algorithm to determine disease stage in clinically defined myocarditis, which was superior compared with T2w and LGE. Most recently, Jeuthe et al. also showed a decline of native myocardial T1 in experimental myocarditis. However, native myocardial T1 is also affected by myocardial fibrosis, which could theoretically confound the use of this technique as an instrument for assessing acute myocardial inflammation, 14, 24 in particular at 3 T. 9,25 Nevertheless, we found that native myocardial T1 at 1.5 T normalized with healing of myocarditis, even in LGE positive, scarred myocardium independent of the clinical subtype of myocarditis ( Table 1 and Figure 4 ). In particular, regional native myocardial T1 was an almost perfect discriminator between acute and healed stages of myocarditis (Figure 6 ), but did not allow a reliable identification of diseased patients at 3-and 12-months FU. In conclusion, our findings agree with the work from Hinojar et al. 15 and Jeuthe et al. 16 suggesting that elevated native myocardial T1 rather represent acute inflammation than chronic injury in patients with myocarditis.
ECV imaging
ECV contains information on native and on post-contrast T1 values which makes ECV sensitive to acute, but also to more chronic, postinflammatory myocardial tissue alterations in terms of myocardial fibrosis as the precursor of DCM. 26, 27 These characteristics of ECV explain the strong discriminative value of a LGE/ECV combination to differentiate between patients with myocarditis from healthy subjects that was recently found by our group. 12 Our findings underline the excellent value of a LGE/ECV combination to differentiate patients with myocarditis from healthy subjects at all stages of myocarditis ( Figure 5 ). On the other hand, ECV appears to be less sensitive to acute myocardial inflammation compared with native myocardial T1 or T2: 13, 14, 28 Although we found a decline in ECV with healing of myocarditis ( Table 1 and Figure 4 ), ECV was inferior to native myocardial T1 and T2 for the discrimination between acute vs. healed stages of myocarditis ( Figure 6 ). In conclusion, ECV (ideally in combination with LGE) seems to be a strong discriminator between diseased and healthy individuals, which is an important diagnostic target, but is not suitable for assessing disease activity. 9, 12, 14 Myocardial T2
In agreement with early experimental findings in myocardial infarction, 29 there is increasing and consistent evidence for the ability of myocardial T2 to assess active myocardial inflammation in myocarditis. 9, 11, 14, 28, 30 Our findings add additional components to this picture: Figure 6 Acute vs. healed myocarditis. ROC curves of global myocardial nT1, pcT1, ECV, T2, the T2w-ratio, gRE, and LGE mass (left) and regional myocardial nT1, pcT1, ECV, T2, and T2w-ratio in LGE positive myocardium (right) to differentiate between patients with acute and healed myocarditis. We found that global and regional myocardial T2 normalized with healing of myocarditis and consequently provided a strong discriminative value between acute and healed stages of myocarditis ( Figure 6 ). Similar to native myocardial T1, regional T2 measurements in LGE positive myocardium provided an excellent performance to discriminate acute from healed stages of myocarditis. Interestingly, the optimal diagnostic cut-offs for myocardial T2 in our study, as depicted by the ROC analyses with >60 ms and >59 ms, were very similar compared with recent studies at 1.5 T by others and our group, 9,11,14 which indicates a transferability of these cut-offs in myocarditis.
Clinical implications
The major potential clinical applications of native myocardial T1 and T2 in myocarditis include the identification of diseased patients in the acute stage of myocarditis but also an individual monitoring of disease activity without the need for contrast media. However, we cannot deduce a clear preference for native myocardial T1 or for myocardial T2 from our findings. The contrast media based techniques LGE and ECV seem to be beneficial to detect more chronic stages of myocarditis. Our findings therefore indicate the need for tailored CMR protocols to address specific clinical scenarios. Non-contrast T1 and/ or T2 mapping seem to be sufficient in clinical scenarios, in which the activity of myocarditis is the major target, whereas contrast-media application with its potential drawbacks 31 seems to be necessary to discriminate diseased patients from structurally healthy individuals independent from the stage of the disease.
Limitations
First, the relatively low FU rate represents a potential limitation of this study (Figure 1 ). In particular, the inevitable exclusion of patients who underwent ICD-and/or assist-device implantation before complete CMR FU constitutes a selection bias, since patients with the worst outcome were not addressed by CMR FUs. In addition, our definition of healing myocarditis depended on clinical and biomarker information, and since we did not perform serial EMB, we cannot exclude the presence of persistent myocardial inflammation. However, improved symptoms, diastolic and systolic LV function and almost normalized biomarkers clearly indicate that our population overall represents patients with healing myocarditis (Table 1) . Secondly, our strict definition of acute myocarditis could have resulted in neglecting patients with mild myocarditis. Thus, the findings and interpretations of this study are confined to our specific population. Thirdly, a potential prognostic value of quantitative CMR tissue characterization in myocarditis was not addressed by this study, which would require large multicenter studies considering the generally low number of patients with adverse outcome. 1,2 Finally, our T1 mapping sequence with a 3(3)5 scheme results in higher normal values for native myocardial T1 12 ( Table 1 ) than other MOLLI and in particular shMOLLI variants that have recently been used at 1.5 T in myocarditis. 10, 13, 15, 28 The 3(3)5 MOLLI scheme is a shorted version of the original 3(3)3(3)5 MOLLI scheme, 32 which accounts for limited breath holding capability in patients. 33 We have recently performed and reported a phantom validation study and established normal values in healthy volunteers as recommended. 12, 23 Furthermore, our normal values and alterations of native myocardial T1 in diseased patients were recently confirmed by others using a similar 3(3)5 MOLLI variant. 9 
Conclusion
Healing of myocarditis can be monitored by native myocardial T1 and T2 measurements without the need for contrast media. Both native myocardial T1 and T2 provide an excellent performance for assessing the stage of myocarditis by CMR and should be included in future protocols.
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